[HTML][HTML] Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects
HY Estupiñán, A Berglöf, R Zain… - Frontiers in cell and …, 2021 - frontiersin.org
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
[HTML][HTML] Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets–beyond B lymphocytes
S Zhu, S Gokhale, J Jung, E Spirollari, J Tsai… - Frontiers in cell and …, 2021 - frontiersin.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation
Introduction: Waldenström's macroglobulinemia (WM), an orphan disease, is a rare low-
grade B-cell lymphoplasmacytic lymphoma with unique clinical features and monoclonal …
grade B-cell lymphoplasmacytic lymphoma with unique clinical features and monoclonal …
Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man
ET Mohammed, T Patel - JAMA oncology, 2021 - jamanetwork.com
Discussion Ibrutinib is a selective Bruton tyrosine kinase inhibitor used for treatment of
several lymphoproliferative disorders, including CLL, mantle cell lymphoma, marginal zone …
several lymphoproliferative disorders, including CLL, mantle cell lymphoma, marginal zone …